Publication:
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

Simple item page
dc.contributor.authorHidalgo-Tenorio, Carmen
dc.contributor.authorSadyrbaeva-Dolgova, Svetlana
dc.contributor.authorEnríquez-Gómez, Andrés
dc.contributor.authorMuñoz, Patricia
dc.contributor.authorPlata-Ciezar, Antonio
dc.contributor.authorMiró, Jose Maria
dc.contributor.authorAlarcón, Arístides
dc.contributor.authorMartínez-Marcos, Francisco Javier
dc.contributor.authorLoeches, Belén
dc.contributor.authorEscrihuela-Vidal, Francesc
dc.contributor.authorVinuesa, David
dc.contributor.authorHerrero, Carmen
dc.contributor.authorBoix-Palop, Lucia
dc.contributor.authorArenas, María del Mar
dc.contributor.authorGarcía-Vázquez, Elisa
dc.contributor.authorArnaiz de las Revillas, Francisco
dc.contributor.authorPasquau, J.
dc.contributor.authorEN-DALBACEN study group
dc.contributor.departmentMedicina
dc.date.accessioned2024-06-21T07:05:44Z
dc.date.available2024-06-21T07:05:44Z
dc.date.issued2023-07-04
dc.description©2023 The Author(s). This manuscript version is an open access article made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/. This document is the Accepted, version of a Published Work that appeared in final form in International Journal of Antimicrobial Agents . To access the final edited and published work see https://doi.org/ 10.1016/j.ijantimicag.2023.106918es
dc.description.abstractObjectives: Infective endocarditis (IE) has high mortality and morbidity and requires long hospital staysto deliver the antibiotic treatment recommended in clinical practice guidelines. We aimed to analyse the health outcomes of the use of dalbavancin (DBV) in the consolidation treatment of IEs caused by Gram-positive cocci and to perform a pharmacoeconomic study. Materials and methods: This observational, retrospective, Spanish multicentre study in patients with IE who received DBV as part of antibiotic treatment in consolidation phase were followed for at least 12 months. The study was approved by the Provincial Committee of the coordinating centre. Results: The study included 124 subjects, 70.2% male, with a mean age of 67.4 years and median Charlson index of 4 (interquartile range: 2.5–6). Criteria for definite IE were met by 91.1%. Coagulase-negative staphylococci (38.8%), Staphylococcus aureus (22.6%), Enterococcus faecalis (19.4%), and Streptococcus Spp. (9.7%) were isolated more frequently, all susceptible to vancomycin. Before DVB administration, 91.2% had undergone surgery; 60.5% had received a second regimen for 24.5 d (16.6–56); and 20.2% had received a third regimen for 14.5 d (12–19.5). DBV was administered to facilitate discharge in 95.2% of cases. At 12 months, the effectiveness was of 95.9%, and there was 0.8% loss to follow-up, 0.8% IE-related death, and 3.2% relapse. Adverse events were recorded in 3.2%. The hospital stay was reduced by 14 d, and there was a mean savings of 5548.57 €/patient vs. conventional treatments. Conclusion: DBV is highly effective, safe, and cost-effective as consolidation therapy in patients with IE by Gram-positive cocci, with few adverse events.es
dc.formatapplication/pdfes
dc.format.extent6es
dc.identifier.citationInternational Journal of Antimicrobial Agents 62 (2023) 106918
dc.identifier.doihttps://doi.org/10.1016/j.ijantimicag.2023.106918
dc.identifier.issnPrint: 0924-8579
dc.identifier.issnElectronic: 1872-7913
dc.identifier.urihttp://hdl.handle.net/10201/142521
dc.languageenges
dc.publisherElsevieres
dc.relationSin financiación externa a la Universidadfes
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0924857923001978es
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectEndocarditises
dc.subjectDalbavancines
dc.subjectCost-effectivees
dc.titleEN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive coccies
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
EN-DALBACEN 2.0 Cohort...pdf
Size:
403.31 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos